1. Home
  2. MGX vs NTIC Comparison

MGX vs NTIC Comparison

Compare MGX & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • NTIC
  • Stock Information
  • Founded
  • MGX 2018
  • NTIC 1970
  • Country
  • MGX United States
  • NTIC United States
  • Employees
  • MGX N/A
  • NTIC N/A
  • Industry
  • MGX
  • NTIC Industrial Specialties
  • Sector
  • MGX
  • NTIC Industrials
  • Exchange
  • MGX NYSE
  • NTIC Nasdaq
  • Market Cap
  • MGX 62.1M
  • NTIC 71.5M
  • IPO Year
  • MGX 2024
  • NTIC N/A
  • Fundamental
  • Price
  • MGX $2.17
  • NTIC $8.90
  • Analyst Decision
  • MGX Strong Buy
  • NTIC Buy
  • Analyst Count
  • MGX 4
  • NTIC 1
  • Target Price
  • MGX $13.00
  • NTIC $20.00
  • AVG Volume (30 Days)
  • MGX 912.4K
  • NTIC 85.0K
  • Earning Date
  • MGX 08-13-2025
  • NTIC 07-10-2025
  • Dividend Yield
  • MGX N/A
  • NTIC 3.16%
  • EPS Growth
  • MGX N/A
  • NTIC N/A
  • EPS
  • MGX N/A
  • NTIC 0.31
  • Revenue
  • MGX $45,263,000.00
  • NTIC $85,268,129.00
  • Revenue This Year
  • MGX N/A
  • NTIC $2.05
  • Revenue Next Year
  • MGX $11.75
  • NTIC $4.70
  • P/E Ratio
  • MGX N/A
  • NTIC $28.09
  • Revenue Growth
  • MGX N/A
  • NTIC 3.46
  • 52 Week Low
  • MGX $1.23
  • NTIC $6.75
  • 52 Week High
  • MGX $5.50
  • NTIC $15.09
  • Technical
  • Relative Strength Index (RSI)
  • MGX 71.83
  • NTIC 64.64
  • Support Level
  • MGX $1.45
  • NTIC $7.91
  • Resistance Level
  • MGX $2.47
  • NTIC $8.97
  • Average True Range (ATR)
  • MGX 0.16
  • NTIC 0.52
  • MACD
  • MGX 0.09
  • NTIC 0.10
  • Stochastic Oscillator
  • MGX 75.47
  • NTIC 87.95

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About NTIC Northern Technologies International Corporation

Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.

Share on Social Networks: